Elevated low-density lipoprotein cholesterol levels and prostate cancer risk: UK Biobank evidence
-
By
-
Alexa, R.
-
Kranz, J.
-
Thöne, M.
-
Grundl, S.
-
Hoffmann, M.
-
Koop, P. H.
-
Feng, C.
-
Schneider, K. M.
-
Schneider, C.
-
Saar, M.
-
February 27, 2026
-
Clinical Scorecard: Association of Increased Low-Density Lipoprotein Cholesterol with Prostate Cancer Risk: Insights from the UK Biobank
At a Glance
| Category | Detail |
|---|
| Condition | Prostate Cancer (PCa) |
| Key Mechanisms | Cholesterol metabolism influences PCa cell proliferation; LDL cholesterol levels inversely associated with PCa risk at population level despite cellular cholesterol dependency |
| Target Population | Men aged 37 to 73 years from the UK Biobank cohort |
| Care Setting | Population-based cohort study with long-term follow-up in UK National Health Service setting |
Key Highlights
- Higher systemic LDL cholesterol (≥ 3.65 mmol/L) is associated with a reduced risk of prostate cancer (HR = 0.83, p < 0.01).
- Elevated alanine aminotransferase (ALT ≥ 50 U/L) also shows a protective association against PCa (HR = 0.69, p < 0.01).
- Family history of prostate cancer (paternal PCa) and better self-rated health index are associated with increased PCa risk.
Guideline-Based Recommendations
Diagnosis
- Consider family history (paternal PCa) and metabolic markers including LDL cholesterol and hepatic enzymes in risk assessment.
- Use ICD-10 coding and longitudinal follow-up data for PCa diagnosis confirmation.
Management
- No direct management changes recommended based on LDL levels; findings highlight complex lipid-PCa risk relationship requiring further research.
Monitoring & Follow-up
- Monitor LDL cholesterol and hepatic function markers as part of metabolic health assessment in men at risk for PCa.
- Incorporate cardiovascular comorbidity screening due to overlapping risk factors.
Risks
- Low LDL cholesterol levels may paradoxically associate with increased PCa risk despite cardiovascular benefits.
- Metabolic disturbances such as diabetes and altered hepatic function may influence PCa risk.
Patient & Prescribing Data
Men aged 37–73 years in UK Biobank cohort with longitudinal follow-up
No direct treatment implications from LDL levels; highlights need for cautious interpretation of lipid-lowering strategies in PCa risk context.
Clinical Best Practices
- Assess comprehensive metabolic and hepatic profiles alongside genetic risk factors for prostate cancer risk stratification.
- Interpret LDL cholesterol levels in context of overall metabolic health and PCa risk, acknowledging the lipid paradox.
- Use multivariable models adjusting for age, ethnicity, BMI, and comorbidities to evaluate PCa risk factors.
References
